Updated Clinical Data for Povetacicept in IgA Nephropathy Support Advancement to Phase 3 Trial

RUBY-3 findings support povetacicept’s ability to induce remission, reduce UPCR, stabilize renal function, and resolve hematuria in patients with IgAN.

Related Keywords

Argentina ,Buenos Aires ,Distrito Federal ,Jonathan Barratt ,Pbudesonide Tarpeyo ,Iga Nephropathy Foundation Jonathan Barratt ,Alpine Immune Sciences Shares Updated Clinical Data ,Alpine Immune Sciences ,World Congress ,University Of Leicester ,Drug Administration ,Iga Nephropathy Foundation ,Immune Sciences ,Mayer Professor ,Renal Medicine ,Full Approval ,Shows Promise ,